TESARX / DOSAGE
Tesamorelin Dosage and Pharmacokinetics in the Trials
The dose used in the studies, the route, and the short plasma half-life set against the sustained IGF-1 effect — described as study parameters, not instructions.
Before the details
This page reports the tesamorelin dose used in the published trials and how the drug moves through the body. It is a description of study parameters, not a how-to. The recurring number is 2 mg per day, given as a subcutaneous injection (under the skin of the abdomen). One quirk worth knowing up front: the peptide itself clears the blood within hours, but its downstream effect — raised IGF-1 — lasts across the whole day, which is why once-daily dosing works. No human-use recommendation is given or implied here.
Daily dose used in the trials
The studied dose is 2 mg subcutaneously once daily. That was the regimen in both pivotal Phase 3 trials and the FDA-approved dosing for the original approved formulations [1][2]. The JAMA hepatic-fat trial and the mechanistic study in healthy men used the same 2 mg/day subcutaneous dose [3][4].
A lower 1 mg/day arm appears in mechanistic and safety work, but the 2 mg/day once-daily paradigm is the extensively studied one [12]. The only route studied in clinical trials, and the only approved route, is subcutaneous injection at an abdominal site. These are the parameters administered in research; this site gives no human dosing instruction.
Half-life and how long tesamorelin stays in the system
Plasma exposure is short. Secondary sources (the FDA label and Mayo Clinic) describe a terminal half-life on the order of 26-38 minutes [13]. Population pharmacokinetic modeling reported an apparent plasma clearance of roughly 1,060 L/h with no clinically relevant demographic covariates [13].
Despite that rapid clearance, the downstream IGF-1 elevation persists across the dosing interval — which is the pharmacological basis for once-daily administration [13]. The peptide leaves the plasma quickly; its biological effect, mediated through growth hormone and IGF-1, outlasts the molecule itself.
Stability and formulation
The trans-3-hexenoic-acid N-terminal modification blocks the DPP-IV cleavage that rapidly inactivates native GHRH, which is what gives tesamorelin a usable duration of action [11]. The approved product is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before subcutaneous injection; the label specifies refrigerated storage and use of the reconstituted solution within a defined window [13].
Research-grade material sold for laboratory use is a different thing from the approved finished drug product. It lacks the purity, potency, and stability oversight of the approved formulation, and the parameters above describe the studied clinical product.
What is the half-life of tesamorelin?
Plasma exposure is short. Secondary sources describe a terminal half-life of roughly 26-38 minutes; population PK modeling reported apparent clearance of about 1,060 L/h [13]. Despite rapid clearance, IGF-1 elevation persists across the dosing interval, supporting once-daily administration.
How long does tesamorelin stay in your system?
The peptide itself clears the plasma within hours (apparent clearance about 1,060 L/h) [13]. Its downstream effect — raised IGF-1 — persists across the once-daily dosing interval, so the biological signal outlasts the molecule's presence in the blood.